Voltage-gated potassium channel Kv1.3 (Kv1.3)

Voltage-gated potassium channel Kv1.3 is an integral membrane protein that functions as a tetrameric ion channel selectively permeable to potassium ions[1][4]. The channel is activated upon changes in membrane potential and enables potassium ion transport down the electrochemical gradient across the cell membrane[1]. Each subunit contains six transmembrane helices (S1-S6), with S1-S4 forming the voltage-sensing domain and S5-S6 forming the ion-conducting pore domain[4]. The selectivity filter contains the highly conserved TXGYG motif responsible for potassium ion coordination and selectivity[4]. Kv1.3 was first discovered in human T lymphocytes and is expressed in various cell types including T and B lymphocytes, macrophages, fibroblasts, platelets, osteoclasts, microglia, oligodendrocytes, and various tissues such as brain, lung, thymus, spleen, and testis[1]. The channel exists in multiple subcellular locations: plasma membrane, inner mitochondrial membrane, and cell nuclei[1]. The channel plays critical roles in cellular processes including membrane potential stabilization, cell proliferation, apoptosis, and immune responses[1][2]. Kv1.3 is particularly important in effector memory T cells, where it mediates cellular immune responses[3]. The channel regulates cellular respiration through both conducting and non-conducting mechanisms, generating reactive oxygen species that drive proliferation[7][12]. Kv1.3 has emerged as a promising therapeutic target for multiple disease categories. In autoimmune and neuroinflammatory diseases, Kv1.3 blockers have shown efficacy in treating multiple sclerosis, with some improving visual field and motor skills in patients[3]. The channel is prominently expressed in immune cells and implicated in inflammation associated with chronic inflammatory conditions[2]. In oncology, Kv1.3 is aberrantly expressed in various cancers including melanoma, pancreatic ductal adenocarcinoma, chronic lymphocytic leukemia, breast cancer, prostate cancer, and various other malignancies[1][5]. Inhibition of Kv1.3 can selectively induce apoptosis in cancer cells expressing the channel while potentially sparing normal cells[1]. Several small molecule inhibitors and peptide toxins have demonstrated antiproliferative and pro-apoptotic effects in preclinical studies[1][3][5]. Despite promising preclinical results, clinical translation remains pending, with ShK-186 being the most advanced candidate, having completed Phase 1 trials for autoimmune diseases[3]. The channel represents a significant therapeutic opportunity across autoimmune disorders, neuroinflammatory conditions, metabolic diseases, and various cancers[2][8].

Other names

Kv1.3 channelKv1.3 potassium channelVoltage-gated potassium channel 1.3mito Kv1.3 (mitochondrial form)T cell potassium channel

Channel blockade/inhibition; inhibition of potassium ion efflux; induction of apoptosis in cancer cells; reduction of T effector memory cell proliferation; suppression of cellular respiration; inhibition of reactive oxygen species generation; modulation of membrane potential.